Biogen (XSWX:BIIB) 3-Year Book Growth Rate : 13.30% (As of Mar. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Biogen 3-Year Book Growth Rate?

Biogen's Book Value per Share for the quarter that ended in Mar. 2024 was CHF88.70.

During the past 12 months, Biogen's average Book Value per Share Growth Rate was 9.80% per year. During the past 3 years, the average Book Value per Share Growth Rate was 13.30% per year. During the past 5 years, the average Book Value per Share Growth Rate was 8.40% per year. During the past 10 years, the average Book Value per Share Growth Rate was 9.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.

During the past 13 years, the highest 3-Year average Book Value per Share Growth Rate of Biogen was 105.70% per year. The lowest was -33.90% per year. And the median was 13.40% per year.

Competitive Comparison of Biogen's 3-Year Book Growth Rate

For the Drug Manufacturers - General subindustry, Biogen's 3-Year Book Growth Rate, along with its competitors' market caps and 3-Year Book Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Biogen's 3-Year Book Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Biogen's 3-Year Book Growth Rate distribution charts can be found below:

* The bar in red indicates where Biogen's 3-Year Book Growth Rate falls into.

Biogen 3-Year Book Growth Rate Calculation

This is the 3-year average growth rate of Book Value per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.

Biogen (XSWX:BIIB) 3-Year Book Growth Rate Explanation

Book Value per Share is the ratio of equity available to common shareholders divided by the shares outstanding. Book value per share effectively indicates a firm's net asset value on a per-share basis. It can be used by investors to gauge whether a stock price is undervalued by comparing it to the firm's market value per share. Theoretically, it is what the shareholders will receive if the company is liquidated.

Biogen 3-Year Book Growth Rate Related Terms

Thank you for viewing the detailed overview of Biogen's 3-Year Book Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Biogen (XSWX:BIIB) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Biogen Inc (XSWX:BIIB) » Definitions » 3-Year Book Growth Rate

Comparable Companies

Traded in Other Exchanges

BIIB:USA BIIB:Mexico 1BIIB:Italy IDP:Germany BIIB34:Brazil BIIB:Austria BIIB:Argentina

Address

225 Binney Street, Cambridge, MA, USA, 02142

Website

https://www.biogen.com

Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel multiple sclerosis drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is copromoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with Sobi) were spun off as part of Bioverativ in 2017. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (post-partum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology-related fields.